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Summarv We report the results of a randomised trial in extensive small-cell lung cancer (SCLC) of a novel
approach to palliatise chemotherapy. A w'idely used 3 w-eekl.b regimen wvas compared with the same drugs given
at half the dose but tuice the frequencx with the same intended overall dose intensitv (DI). A total of 167
patients defined as having extensive SCLC with adverse prognostic features were randomised to receive either a
3 weekly regimen of cisplatin 60 mg m-' 2. on day 1 and etoposide 120 mg m is. on da% 1 and 100 mg
b.d. orallv on days 2 and 3 alternating With cyclophosphamide 600 mg m-' 2LV.. doxorubicin 50 mg m-- iL.
and vincristine 2 mg ix. all on day 1 for a maximum of six courses (3 w-eekly): or treatment with the same
drugs but with each course consisting of half the 3 weekly dose given evern 10 or 11 days for a maximum of 12'
courses. In the 10 11 day regimen overall response rate w-as 58.9°o (950o CI. 47.9-69.20o) with 12.80o
complete responses (CR). For the 3 w-eekly treatment the overall response rate A-as 44.90o (950o CI. 35.0-
55.55/0) with 10.1% CR. Median survival wvas similar in the two arms at 6.4 months (950o CI. 4.9-7.3 months)
and 5.8 months (95%o CI. 4.0-6.6 months) respectively. SurVxial at 1 year was 9.90o (950o CI. 5.0- 18.50o) and
8.90o (95°o CI. 4.6-16.6°oo). The 9500 CI for the difference in survi-al at 1 xear is 7.090o to -9.090°.
Haematological toxicity and treatment delays owing to infection w-ere more frequent with the 10 11 day
regimen but other toxicities were equal in both arms. Other aspects ofquality of life were measured in a small
representative cohort of patients using a daily diary card (DDC). There was a trend of improved quality of life
on the 10 11 dav arm. but there was little difference between the tu-o treatments. The trial show-s that a low-
dose high-frequencv regimen with the same DI as conventionall1 scheduled chemotherapy ezives similar
response rates and survival. This and other modifications of the schedule may offer new approaches to
palliative treatment of advanced cancer. However. in this trial there w-as no significant benefit in toxicity or
other aspects of quality of life.
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Despite the chemosensitivity of small-cell lung cancer there
has been little improvement over the last 10 years in response
rates and survival for those patients who have extensive
disease (Comis, 1993) and particularly for those with poor
prognostic features. Overall. only 2.2% of extensive disease
patients Will be alive at 2 years (Souhami and Law. 1990).
For these patients and for elderly patients. attention has been
turned to palliative chemotherapy. such as the use of oral
etoposide (Byrne and Carney. 1994: Carney et al.. 1990).
Other approaches to palliation are possible. It has been
suggested (Hryniuk. 1988) that dose intensity of chemother-
apy is a major determinant of response and survival in
cancer. Since acute chemotherapy toxicity is related to dose
we hypothesised that major dose reduction might lessen the
acute toxicity of chemotherapy without worse survival
provided that the dose intensity (DI) of treatment was
maintained.
The present report describes the results of a trial in which
this novel method of palliation has been assessed. A 3 weekly
conventional alternating chemotherapy regimen of cyclopho-
sphamide. doxorubicin and vincristine and cisplatin and
etoposide based on that introduced by the National Cancer
Institute of Canada (Feld et al.. 1987) was used as the
reference treatment. These drug combinations have been
widely used in the treatment of SCLC. The regimen was
modified for poor prognosis patients by reducing the doses of
cyclophosphamide from 1 g m-' to 600 mg m- and the
cisplatin from 25 mg m-- on days 1-3 to 60 mg m-' on dav
1. The etoposide was modified to alloxx the drug to be given
by mouth on days 2 and 3. In this sA-ay each cycle had only
one day of intravenous treatment. The novel regimen
consisted of the same drugs given at half the dose on each
cycle, but at tWice the frequency. Quality of hfe was assessed
in a small cohort using a daily diary card (Geddes et al..
1990).
Between July 1988 and December 1992. 167 patients were
entered into the study from the participating centres. Patients
were eligible if they had SCLC diagnosed by histology
(bronchial biopsy. lymph node biopsy) or by cytology from
bronchial washings, pleural aspirate or sputum specimen: if
they were aged 75 years or less and had both extensive
disease and poor prognostic factors defined as a performance
status of ECOG 2 or 3 and or an alkaline phosphatase (ALP)
greater than 1.5 times the upper limit of normal (Rawson and
Peto. 1990: Souhami et al.. 1985). Renal function had to be
adequate for cisplatin chemotherapy. Patients A-ere excluded
if they had a previous malignancy other than non-
melanomatous skin cancer in the preceding 3 years: if they
had received previous chemotherapy or radiotherapy except
for emergency radiotherapy for superior vena caval obstruc-
tion or any medical condition which would preclude the use
of chemotherapy.
Initial investigations included chest radiograph. full blood
count, blood urea and electroly-tes. liver function tests. serum
creatinine or EDTA renal clearance. li-er ultrasound and
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bone isotope scan. Brain scans were only performed if there
was a clinical indication. Extensive disease was defined as
disease outside the hemithorax but excluding ipsilateral
supraclavicular lymph nodes. Diagnostic specimens were
reviewed centrally. Informed consent was obtained in
accordance with the individual ethical committee of the
participating centres.
Materials and Medhds
Treatment
The 3 weekly regimen consisted of cisplatin 60 mg m-2 i.v.
on day 1 and etoposide 120 mg m-2 i.v. on day 1 and 100 mg
b.d. orally on days 2 and 3, alternating every 21 days with
cyclophosphamide 600 mg m-2 i.v., doxorubicin 50 mg m-2
i.v. and vincristine 2 mg i.v. all on day 1. A total of six
courses was planned. The 10/11 day regimen consisted of
cisplatin 30 mg m-2 i.v. on day 1 with etoposide 60 mg m-2
i.v. day 1 and 100 mg o.d. orally on days 2 and 3 alternating
with cyclophosphamide 300 mg m-2 i.v., doxorubicin
25 mg m-2 i.v. and vincristine 1 mg i.v. all on day 1. A
total of 12 courses (six with each drug combination) was
planned. Separate dose modification schedules to deal with
haematological toxicity and based on the pretreatment full
blood counts were prepared for each arm and are shown in
Table I. The dose reductions were made at a lower level of
white blood counts in the 10/11 day arm because in pilot
studies it was found that the leucopenia is more gradual than
in 3 weekly treatment. Anti-emetic therapy was not
standardised in either arm of the study but usually consisted
of ondansetron with or without dexamethasone.
Response criteria
Response was assessed by chest radiograph and by repeating
any investigation that was used to define tumour extent.
Bronchoscopy was not used routinely to assess response. A
complete response (CR) was defined as complete radiological
clearing of the chest radiograph and disappearance of all
symptoms, signs, biochemical abnormalities and normal-
isation of investigations that had indicated metastatic
disease. Bone scans which were abnormal at presentation
were not always repeated. A partial response (PR) was a 50%
or greater reduction in the size ofthe tumour measured as the
sum of the two maximum diameters at right angles to each
other on the chest radiograph, with improvement or stability
at other disease sites. Response was measured over a 3 week
period to coincide with patients' hospital attendances for
chemotherapy. Both CR and PR had to be maintained for a
minimum of 3 weeks. Stable disease (SD) was any response
less than 50% on chest radiograph, with all other disease sites
or symptoms remaining the same or having diminished in
size. Progressive disease (PD) or relapse was recorded if the
tumour mass at any site enlarged or reappeared 3 weeks after
the last course of chemotherapy or during the follow-up
period, or if a new metastasis appeared. Central nervous
system relapse was confirmed by computerised tomography
brain scan, liver relapse by ultrasound scans and deteriorat-
ing liver function and bone relapse by isotope scan. Ifrelapse
occurred after the first two courses of chemotherapy had
been given, the patient was treated symptomatically.
All patients on follow-up were reassessed every 4 weeks
with chest radiograph, full blood count, urea, electrolytes,
liver function tests and performance status. Relapse status
and site were recorded as described above.
Toxicity
Toxicity caused by chemotherapy was recorded by physicians
at each visit. Nausea and vomiting, haematuria, infection,
neuropathy and mucositis were recorded following the WHO
guidelines.
Randomisation and statistical methods
Randomisation was by telephone to the trials centre and
patients were stratified by centre. Block randomisation lists
were originated and kept at the Trials Office. All eligible
patients were analysed according to the treatment to which
they were originally randomised and according to their
recorded tumour stage at randomisation.
Chemotherapy DI was calculated for the duration of the
administered chemotherapy, i.e. as measured from the first
day of the first chemotherapy cycle to the first day of the last
chemotherapy cycle. Dose reductions of myelosuppresive
drugs were planned so they would affect all drugs in equal
proportion; in this way no assumption of equivalent anti-
tumour effect of each component should affect the DI
calculation and DI can be calculated for the regimen as a
whole. The graphical method of plotting the results has been
described previously (Miles et al., 1991; Souhami et al., 1994).
The final calculated maximum achieved dose intensity
corresponds to the formula (RDo/IDo)/(RDu/IDu), where
RDo =received dose, IDo =intended dose, RDu =received
duration and IDu =intended duration.
The end points of the trial were death from cancer,
progression and quality oflife. The trial was designed to have
a 90% chance of detecting a 10% improvement in 1 year
survival for the 3 weekly arm at the significance level of 5%
Table I Dose reduction criteria
White cell count Platelets
Regimen ( x 1091- ) (x 1091-) Modification
lOll day >2 total WBC I100 None
or > I neutrophils
<2 total WBC <100 Delay I week
or <1 neutrophils
After I week's delay:
<2 total WBC <100 750 for that cycle
or < I neutrophils
3 weekly >4 total WBC .120 None
or .2 neutrophils
3.0-3.9 total WBC 100- 119 Etop/Cyclo/Dox. 75% for that cycle
or 1.5-1.9 neutrophils
2.0-2.9 total WBC 75-99.9 EtoplCyclo Dox. 50% for that cycle
or I - 1.4 neutrophils
<2.0 total WBC <75 Delay I week. Continue at 50%
or <I neutrophils Etop/Cyclo/Dox
Etop, etoposide; Cyclo, cyclophosphanuide; Dox, doxorubicin.Pr chuniosrpinsC.C
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(one-sided test). Survival and progression-free interval were
calculated from date of diagnosis. The Kaplan-Meier
estimate was used to calculate survival and progression-free
curves and treatment comparisons in these measurements
were made using the log-rank test. (Peto et al., 1977) Median
follow-up was calculated using the 'reverse' Kaplan-Meier
analysis. Further comparisons between treatments were
performed using a two-tailed t-test; toxicity was analysed
using contingency tables with the xI statistic.
Quality of life measwement
The eight question DDC has been previously analysed for
reliability and validity and compared with the Spitzer quality
of life index and the EORTC quality of life questionnaire
(Geddes et al., 1990). Its use in randomised trials in SCLC
has been reported previously (Earl et al., 1991; Fayers et al.,
1991). To obtain maximum compliance and to standardise
data collection, four participating centres were designated for
quality of life assessment. One member of staff was
responsible for distribution and collection of the DDCs.
Patients considered eligible for the study were asked before
chemotherapy was started, if they would be willing to
complete DDCs. They were asked to complete the cards
daily from the first day of chemotherapy and for a period of
up to 8 months. This period was intended to cover the entire
period of chemotherapy with some months of follow-up.
Patients were asked to complete the cards at the same time
each day. Where possible, explanations of the study and the
DDC were given in the presence of a relative. The cards were
checked at each chemotherapy visit and replaced when
necessary. Following treatment all patients were seen
monthly for the first year. In the follow-up period all
patients still completing DDCs were given the remainder of
their cards to be returned by post
Compliance was calculated as the percentage of daily
scores available compared with the number that would have
Table H Patient characteristics
Allocated treatment
JO/Il day 3 weekly
Numbers 78 89
Eligible 73 89
Age (years)
Range 39-75 38-74
Median 63.0 63.0
Sex
Male 51 57
Female 27 32
Performance status
0 10 7
1 19 22
2 27 34
3 22 26
been available on all possible days. Mean compliance was
then calculated for each arm in the trial and compared using
the Mann-Whitney test.
Within each treatment arm the number of scores over a
specified level, as a percentage of all available scores, was
calculated for each question, for each day, for the period of
analysis and displayed graphically. The Mann-Whitney test
was used to compare differences in these scores between the
treatment arms. Where appropriate the t-test and Pearson
correlation product were used for analyses. Comparisons of
treatment variables between arms and between the QOL
group and all patients within the trial were done using a 2-
way ANOVA, followed by a multiple comparison procedure.
Results
Of the 167 patients, 78 were randomised to the 10/11 day
treatment arm and 89 to the 3 weekly arm. This imbalance
occurred because patients were stratified by hospital, some of
which entered only a few patients. In a trial of this size
imbalances can occur unless minimisation is used. On the 10/
11 day arm, five patients were ineligible (two had non-small-
cell lung cancer and three were subsequently shown to have
limited disease). Patient characteristics at entry are shown in
Table II. Both groups were well matched for age, sex and
performance status. Biochemical and haematological para-
meters (Table Ill) were well balanced although the mean
GTP was slightly but not significantly higher on the 10/11
day arm and the mean AST slightly higher on the 3 weekly
arm. Data from five patients in the 10/11 day arm and three
patients in the 3 weekly arm were insufficient to form part of
the dose intensity analysis but were included in the other
analyses. All patients have finished chemotherapy and the
median follow-up is 3 years.
Chemotherapy treatment
The treatment received is summarised in Table IV. The mean
total dose received between the two arms was similar and was
59.3% of that intended for the 10/11 day arm and 60.2% for
the 3 weekly arm. The received DI with the 10/11 day
regimen was 87.1% of the intended dose and 90.1% for the 3
weekly treatment. The percentage total dose is lower than the
DI because of patients who did not complete chemotherapy.
The number of courses received on the 10/11 day arm was
double that on the 3 weekly arm (7.5 and 3.7 respectively,
Table IV). The main reason for failure to complete therapy
(Table V) was haematological toxicity with 20% of patients
receiving the 10/11 day treatment having reductions
compared with 8% of the 3 weekly patients. There was no
difference in the number of treatment delays, 14.7% (10/11
day) and 16.3% (3 weekly). Delays owing to infection
occurred in 9.3% of patients on the 10/11 day protocol
compared with 1.2% of the 3 weekly patients. There was no
difference in each arm for the proportion of patients not
completing chemotherapy (59.0%, 10/11 day and 57.3%, 3
weekly). Table IV shows that the main reasons for not
Table iM Patient biochemical and haematological profiks at randomisation
Allocated treatnent
10/11 day 3 weeklv
Mean 95% CI Mean 95% CI
Alkaline phosphatase 406.1 324.1-488.0 479.8 388.7-571.0
GTP 278.7 165.3-392.1* 183.8 131.3-236.4
AST 57.8 40.0-75.7* 72.5 47.9-97.1
Albumin 35.8 34.8-36.9 34.8 33.7-35.9
Sodium 131.6 128.2-134.9 133.3 131.7- 134.8
*P>0.I for comparison between the two regimens.PaFUiave dchuuah.rapy in SCIC
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Table IV Summary of chemotherapy treatment
Treatment arm
10/11 day 3 weekly
Duration (days)
Mean 79.2
95% CI 66.7-91.6
Percent intended dose
Mean 59.3
95% CI 50.5-68.1
Percent intended intensity
Mean 87.1
95% CI 81.9-92.2
No. of courses
Mean 7.5
95% CI 6.5-8.6
Patients not completing chemotherapy
_ 46 (59.0%)
95% CI 48.1 -69.9
Reasons for not completing chemotherapy
Progessiona 26 (33.3%)
Voluntary withdrawals 8 (10.3%)
Toxicity 5 (6.4%)
Other 7 (9.0%)
61.8
51.7-72.0
60.2
52.2-68.1
90.1
85.8-94.3
Table VI Response to treatment
Allocated treatment arm
10/11 day 3 weekly
Response % (95% CI) % (95% CI)
Complete 12.8 (7.1 -22.0) 10.1 (5.4-18.1)
Partial 46.1 (35.5-57.1) 34.8 (25.7-45.1)
Stable 16.7 (10.0-26.5) 13.5 (7.9-22.1)
Progression 9.0 (4.4-17.4) 10.1 (5.4-18.1)
Toxic death 0 7.9 (3.9-15.4)
Inevaluable 15.4 (9.0-25.0) 23.6 (16.0-33.4)
X2=9.49, d.f. =5, P>0.05.
3.7
3.3-4.2
51 (57.3%)
47.0-67.6
30 (33.7%)
6 (6.7%)
12 (13.5%)
3 (3.4%)
aThe figure given is progression at any stage during the
chemotherapy treatment, even if there had been previous response.
[9% and 10.1% of patients had progressive disease with no prior
response (Table VI).]
Table V Number and per cent of patients who had at least one
chemotherapy cycle reduced or delayed
Treatment arm
10/11 day 3 weekly
n % n %
Dose reduced (%) 30 40 26 30.2
Haematological toxicity 15 20 7 8.1*
Physician's decision 15 20 12 14
Other 5 6.7 10 11.6
Treatment delayed (%) 33 44 27 31.4
Haematological toxicity 11 14.7 14 16.3
Infection 7 9.3 1 1.2*
Other medical condition 8 6.7 3 3.5
Patient's wish 2 2.7 1 1.2
Other 7 9.3 11 12.8
*P<0.05.
completing chemotherapy were tumour progression, toxicity
and patient's wish to discontinue. These were equal in both
arms.
Response and survival
Response to treatment is shown in Table VI. The overall
response rate was 58.93% on the 10/11 day arm (CR+PR)
and 44.9% on the 3 weekly arm (CR+PR). In the 10/11 day
arm ten patients (12.8%) were inevaluable for response. Two
patients died before the first cycle of chemotherapy, seven
progressed or withdrew before cycle 2 and there was one
unrelated death. In the 3 weekly arm 22 patients (24.7%)
were inevaluable according to the protocol criteria. Two died
before the first cycle and another refused chemotherapy.
Twelve patients died before the second cycle, three withdrew,
three died of other causes and there was one toxic death. All
these patients are included in the survival analysis.
Overall survival is shown in Figure 1. There was no
significant difference in survival between the two groups.
Median survival (MS) on the 10/11 day arm was 6.4 months
(95% CI, 4.9-7.3) and for the 3 weekly arm MS was 5.8
months (95% CI, 4.0-6.6). Survival at 1 year on the 10/11
-
C,)
2 3 0
Years
Figue 1 Survival (all patients)..... (10/11 day) MS 6.4 months
(95% CI, 4.9-7.3); __ (3 weekly) MS 5.8 months (95% CI,
4.0-6.6). P=0.7.
day arm was 9.9% (95% CI, 5.0-18.5) and 8.9% (95% CI,
4.6-16.6) on the 3 weekly arm. Survival at 2 years was 4.3%
(95% CI, 1.6-11.3) and 2.5% (95% CI, 0.7-8.2) respec-
tively. The 95% CI, for the absolute difference in survival at
1 year is -7.09% to +9.09% and at 2 years is - 5% to
+7.34%. The trial excludes a survival difference of 15% at
80% power.
The hazard ratio for survival was 0.91 in favour of the 10/
11 day arm (95% CI, 0.79-1.52) Using these data we can
produce limits for the size of the possible benefit of one
treatment compared with another (Haybittle, 1979). For the
10/11 day regimen, at 1 year there is a 1 in 8 chance of 8%
benefit, a 1 in 40 chance of 12% and 1 in 200 of 15%
improvement in survival. There was no significant difference
between the two groups with respect to site of relapse, the
most common first site being at the primary tumour.
Toxicity and quality of life
The major toxicities were haematological, nausea and
vomiting (Table VII). Leucopenia was more frequent with
the 10/11 day regimen with more grade 1-2 infections in this
group. Other toxicities were equally distributed, in particular
nausea and vomiting were no less frequent or severe with the
10/11 day treatment.
A cohort of 49 patients, which consisted of all patients
entered from one centre and its associated hospitals, were
asked to complete DDCs. Of these, 14 refused (eight and six
in 10/11 day and 3 weekly arms respectively. No significant
differences were found in the distributions of age, sex and
performance status between the arms in the QOL group or
when compared with the full set of trial patients. There was
no difference in dose intensity between groups or between
arms (Table VIII).Paffmov co deni y in sac
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Table VII Maximum toxicities (number and %) experienced by patients during treatment (WHO scale)
10 11 day 3 weekly
0 1-2 3-4 0 1-2 3-4
Toxicity grade n (%) n (%) n (%) n (%) n (%) n (%) P-value
Leucopenia 14 (21.2) 37 (56.1) 15 (22.7) 31 (50) 27 (43.5) 4 (6.5) <0.01
Thrombocytopenia 61 (88.4) 6 (8.7) 2 (2.9) 55 (88.7) 5 (8.1) 2 (3.2) >0.1
Nausea and vomiting 17 (25.0) 36 (53) 15 (22) 24 (36.9) 25 (38.5) 17 (26.1) >0.1
Haematuria 65 (97.0) 2 (3) NA 64 (98.5) 1 (1.5) NA >0.1
Infection 33 (49.3) 31 (46.3) 3 (4.5) 47 (72.3) 1.5 (23) 3 (4.6) <0.05
Neuropathy 46 (68.7) 17 (25.4) 4 (6) 48 (73.8) 17 (26.1) 0 >0.1
Mucositis 39 (58.2) 27 (51.3) 1 (1.5) 43 (66.2) 19 (29.3) 3 (4.6) >0.1
NA, not applicable.
Table VIII Details of the chemotherapy treatment in the QOL
group and in all patients (2-way ANOVA with no significant
interaction)
10/11 day 3 weekly
QOL All QOL All
group patients group patients
Duration (days) 97.7 76.4 99.5 57.1a
Percentage dose 71.6 57.9 87.8 57.3a
Percentage intensity 91.7 90.4 92.8 93.0
No. of courses 8.9 7.0 5.4 3.4a
Withdrawal 2 5 0 5
alndicates significantly different QOL group (P<0.005).
Compliance was 62% (68.6% in the 10/11 day and 52% in
the 3 weekly arm) for the intended period of analysis.
Because of the fall in number of respondents over time, the
first 80 days were used for analysis. During this time there
was a minimum of ten respondents in each arm and
compliance was 79.3% in the 10/11 day arm and 82.6% in
the 3 weekly arm.
Percentage of scores which reported any adverse event (i.e.
a value different from zero) were slightly but significantly
worse with respect to vomiting, happiness, appetite, general
well-being and activity in the 3 weekly arm (Table IX) but
there was no difference in reported nausea, pain and sleep.
There was no significant correlation between physician-
reported nausea and vomiting and the relevant diary cards,
but there was a correlation of 0.625 between ECOG and
DDC activity scores (205 courses).
Disasso
The hypothesis which led to this study was that, if DI is the
major determinant of tumour response and survival (rather
than drug schedule) it might be possible to reduce
chemotherapy toxicity without loss of anti-tumour effect by
a low-dose/high frequency regimen. SCLC patients with
extensive disease and poor prognostic features are rarely
cured by chemotherapy. Trials of palliation are therefore of
great importance in this group (Comis, 1993; Byrne and
Carney, 1994). Trials of chemotherapy dosage in SCLC have
not shown a benefit from a modest increase in dose above the
conventional therapeutic level (Klasa et al., 1991; Ihde et al.,
1994; Figueredo et al., 1985). In other cancers dose reduction
without increase in frequency has been shown to reduce
response and survival (Tannock et al., 1987).
We chose the regimen described by Feld et al. (1987) as a
basis for our study since this represents a standard
chemotherapy combination in SCLC. We modified the drug
dosages to allow this regimen to be given to a group of
patients with an expected poor prognosis. The results
reported here indicate that the strategy of half-dose/double
Table IX The percentage ofpatients reporting adverse DDC scores
during the first 80 days
First 80 days (median of % patients)
Variable 10/11 J aJ 3 weekly Difference P-value
Nausea 25.0 22.2 2.9 >0.1
Vomiting 6.7 10.0 -3.3 <0.0005
Happiness 72.2 80.0 -7.8 <0.0001
Appetite 41.9 64.1 -22.2 <0.0001
Pain 42.9 41.7 1.2 >0.1
General well-being 60.0 66.7 -6.7 <0.005
Activity 73.0 93.3 -20.3 <0.0001
Sleep 69.2 69.2 0.0 >0.1
frequency appears to be equivalent to conventional 3 weekly
treatment with respect to response and survival, lending
support to the concept of DI as an important determinant of
outcome. To our knowledge, there have been no other studies
approaching this question in this way. However, owing to the
sample size, the results do not exclude a survival difference
smaller than 12% at 1 year for either regimen.
The response rates are low, but are comparable with other
studies of extensive disease (Medical Research Council Lung
Cancer Working Party, 1993). Survival is however worse than
in other studies which typically report median survivals of8-
12 months (Earl et al., 1991; Medical Research Council Lung
Cancer Working Party, 1993). It is stressed that the present
study selected only patients showing very adverse prognostic
characteristics: extensive disease, an elevated ALP and/or PS
2 or 3. This constitutes the poorest prognostic category in
SCLC, even patients with PS 0 or 1 who have extensive
disease and elevated ALP having a poor survival (Rawson
and Peto, 1990; Souhami et al., 1985).
We have found, contrary to our starting hypothesis, that the
low-dose/high frequency regimen was not a preferred method
of palliation. Leucopenia occurred more often with this
regimen leading to an increased frequency of dose reduction.
Myelosuppression was also the major toxicity of the weekly
regimens described by Souhami et al. (1994) and Sculier et al.
(1993). The more detailed quality of life measurements, using
the DDC which is very sensitive to acute effects of
chemotherapy, were made on only a relatively small cohort of
patients. These patients were however representative of the
whole group in terms ofcharacteristics, response and survival,
and were balanced for these characteristics between the two
treatment arms. The results showed a lower frequency of
vomiting, better general well-being, activity and happiness and
less anorexia. Although statistically significant, the degree of
difference was however small and was offset by the increased
frequency of hospital visits. The physician's toxicity score
showed no differences between the two regimens, but other
studies have shown discordance between doctor and patient
with respect to quality oflife measurement (Slevin et al., 1988;
Clark and Fallowfield, 1986).Paue chun -erapyi SCLC $0 LE Jafes et a
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We conclude that this novel method of palliation is not of
value in SCLC. However, the fact that response and survival
were maintained implies that other variations of dose and
schedule could be explored in SCLC and other advanced
cancers in which the aim is to palliate without loss of anti-
tumour efficacy.
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